{"schema_version":"secwatch.filing_event.v1","accession":"0001937653-23-000020","form_type":"8-K","ticker":"ZYME","cik":"0001937653","company_name":"Zymeworks Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.603441+00:00","generated_at":"2026-06-15T14:28:40.287537+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zymeworks Q1 net loss down 66% to $24.4M; revenue surges to $35.6M on Jazz deal; cash runway through 2026","bullets":["Net loss $24.4M vs $72.6M in Q1 2022 (-66%); revenue $35.6M vs $1.9M, driven by Jazz collaboration.","Cash & securities $412.4M; reaffirms 2023 net operating cash burn guidance $90-120M and cash runway through at least 2026.","R&D expense decreased $16.6M to lower levels; Non-GAAP R&D down $14.7M.","Will present pivotal Phase 2b zanidatamab data at ASCO (oral presentation); ZW191/ZW171 on track for IND filings in 2024.","Board strengthened with appointment of Derek Miller, adding business development and commercial expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001937653-23-000020","json":"https://secwatch.observer/filing/0001937653-23-000020.json","markdown":"https://secwatch.observer/filing/0001937653-23-000020.md","text":"https://secwatch.observer/filing/0001937653-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/0001937653-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/zyme-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T14:28:40.287537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"86bed76765aa1242c402811ce49bc8b059c08e15","claim":"Zymeworks Inc. reported first quarter ended March 31, 2023 results: net income $24.4 million. Guidance reaffirmed.","evidence_excerpt":"Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics , today reported financial results for the first quarter ended March 31, 2023 and provided a summary of recent business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1937653/000193765323000020/0001937653-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$24.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}